作者
David B Solit, Fuzhong F Zheng, Maria Drobnjak, Pamela N Münster, Brian Higgins, David Verbel, Glenn Heller, William Tong, Carlos Cordon-Cardo, David B Agus, Howard I Scher, Neal Rosen
发表日期
2002/5/1
期刊
Clinical cancer research
卷号
8
期号
5
页码范围
986-993
出版商
American Association for Cancer Research
简介
Purpose: Ansamycin antibiotics, including 17allylamino-17-demethoxygeldanamycin (17-AAG), inhibit Hsp90 function and cause the selective degradation of signaling proteins that require this chaperone for folding. Because mutations in the androgen receptor (AR) and activation of HER2 and Akt may account, in part, for prostate cancer progression after castration or treatment with antiandrogens, we sought to determine whether an inhibitor of Hsp90 function could degrade these Hsp90 client proteins and inhibit the growth of prostate cancer xenografts with an acceptable therapeutic index.
Experimental Design: The effect of 17-AAG on the expression of Hsp90 regulated signaling proteins in prostate cancer cells and xenografts was determined. The pharmacodynamics of target protein degradation was associated with the toxicology and antitumor activity of the drug.
Results: 17-AAG …
引用总数
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024533385054403143283333251717271315101081164